Serum CXCL10/IP-10 may be a potential biomarker for severe Mycoplasma pneumoniae pneumonia in children

BMC Infect Dis. 2021 Sep 4;21(1):909. doi: 10.1186/s12879-021-06632-4.

Abstract

Background: How to early distinguish the severity of Mycoplasma pneumoniae pneumonia (MPP) is a worldwide concern in clinical practice. We therefore conducted this study to assess the relationship between levels of serum inflammatory chemokines and the severity of MPP.

Methods: In this prospective study, we enrolled 39 children with MPP, whose clinical information was collected, blood samples were assayed for cytokines and chemokines by ELISA.

Results: The levels of serum CXCL10 in children with severe MPP were significantly higher than those in children with mild MPP (2500.0 [1580.9-2500.0] vs. 675.7 [394.7-1134.9], P < 0.001). Measurement of CXCL10 levels in serum enabled the differentiation of children with severe MPP with an area under the curve (AUC) of 0.885 (95 % CI 0.779-0.991, P < 0.001), with a sensitivity of 81.0 % and a specificity of 83.3 %.

Conclusions: Serum CXCL10 level may be a potential biomarker for severe MPP in children.

Keywords: CXCL10/IP-10; Children; Mycoplasma pneumoniae pneumonia; Prediction.

MeSH terms

  • Biomarkers
  • Chemokine CXCL10
  • Child
  • Humans
  • Mycoplasma pneumoniae*
  • Pneumonia, Mycoplasma* / diagnosis
  • Prospective Studies

Substances

  • Biomarkers
  • CXCL10 protein, human
  • Chemokine CXCL10